ArticleBMC nephrology2025
Efficacy and safety of telitacicept in the treatment of immunoglobulin a nephropathy: a real-world, single-center, retrospective study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy and safety of telitacicept for rituximab-refractory membranous nephropathy.International urology and nephrology · 2026Article
- Real-world study of telitacicept in the treatment of IgA nephropathy.Frontiers in immunology · 2026Article
- Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study.Frontiers in immunology · 2026Article
- Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundImmunoglobulin A nephropathy (IgAN), the most common glomerular disease, is characterized by immune complex deposition and abnormal complement system activation. Telitacicept targets B cells through multiple mechanisms, potentially offering therapeutic benefits in IgAN. This retrospective study aimed to evaluate the efficacy and safety of telitacicept.
methodsEleven patients with IgAN treated with telitacicept (160 mg, weekly) between August 2022 and December 2024 were included. The minimum follow-up period was 24 weeks, and the primary endpoint was renal remission rate at the final visit.
resultsAmong the 11 patients, 6 (54.5%) achieved partial remission, including 3 (27.3%) with complete response. Following telitacicept treatment, 24-h proteinuria decreased from a baseline of 1.77 g/day (interquartile range [IQR]: 1.31-5.19 g/day) to 1.04 g/day (IQR: 0.27-1.41 g/day) at the last follow-up (P < 0.05), demonstrating a significant reduction in proteinuria. Urinary red blood cell counts decreased from 52.81 ± 110.95 to 9.62 ± 11.44 per high-power field. The main adverse reaction was an upper respiratory tract infection, with no serious events reported.
conclusionThis study provided preliminary evidence that telitacicept may reduce proteinuria in patients with IgAN, with no serious safety concerns observed during this study. These preliminary real-world findings support the potential role of telitacicept in IgAN management and warrant confirmation in prospective multicenter studies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.